Literature DB >> 33634031

Game of Bones: How Myeloma Manipulates Its Microenvironment.

Tyler Moser-Katz1, Nisha S Joseph1, Madhav V Dhodapkar1, Kelvin P Lee2, Lawrence H Boise1.   

Abstract

Multiple myeloma is a clonal disease of long-lived plasma cells and is the second most common hematological cancer behind Non-Hodgkin's Lymphoma. Malignant transformation of plasma cells imparts the ability to proliferate, causing harmful lesions in patients. In advanced stages myeloma cells become independent of their bone marrow microenvironment and form extramedullary disease. Plasma cells depend on a rich array of signals from neighboring cells within the bone marrow for survival which myeloma cells exploit for growth and proliferation. Recent evidence suggests, however, that both the myeloma cells and the microenvironment have undergone alterations as early as during precursor stages of the disease. There are no current therapies routinely used for treating myeloma in early stages, and while recent therapeutic efforts have improved patients' median survival, most will eventually relapse. This is due to mutations in myeloma cells that not only allow them to utilize its bone marrow niche but also facilitate autocrine pro-survival signaling loops for further progression. This review will discuss the stages of myeloma cell progression and how myeloma cells progress within and outside of the bone marrow microenvironment.
Copyright © 2021 Moser-Katz, Joseph, Dhodapkar, Lee and Boise.

Entities:  

Keywords:  MGUS; bone marrow microenviroment; multiple myeloma; myeloma therapy; smoldering myeloma

Year:  2021        PMID: 33634031      PMCID: PMC7900622          DOI: 10.3389/fonc.2020.625199

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  173 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Molecular pathogenesis and a consequent classification of multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

3.  High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

Authors:  H Avet-Loiseau; J Y Li; T Facon; C Brigaudeau; N Morineau; F Maloisel; M J Rapp; P Talmant; F Trimoreau; A Jaccard; J L Harousseau; R Bataille
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

4.  Smoldering multiple myeloma.

Authors:  R A Kyle; P R Greipp
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

Review 5.  Integrin-mediated drug resistance in multiple myeloma.

Authors:  J S Damiano; W S Dalton
Journal:  Leuk Lymphoma       Date:  2000-06

6.  IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

Authors:  Lori A Ehrlich; Ho Yeon Chung; Irene Ghobrial; Sun Jin Choi; Francesca Morandi; Simona Colla; Vittorio Rizzoli; G David Roodman; Nicola Giuliani
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

7.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

8.  Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma.

Authors:  Francesco Maura; Even H Rustad; Venkata Yellapantula; Marta Łuksza; David Hoyos; Kylee H Maclachlan; Benjamin T Diamond; Benjamin D Greenbaum; Gareth Morgan; Alexander Lesokhin; Elli Papaemmanuil; Ola Landgren
Journal:  Leukemia       Date:  2019-12-13       Impact factor: 11.528

Review 9.  How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.

Authors:  Adam D Cohen; Noopur Raje; Jessica A Fowler; Khalid Mezzi; Emma C Scott; Madhav V Dhodapkar
Journal:  Clin Cancer Res       Date:  2019-10-31       Impact factor: 12.531

10.  Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.

Authors:  E Kastritis; E Terpos; L Moulopoulos; M Spyropoulou-Vlachou; N Kanellias; E Eleftherakis-Papaiakovou; M Gkotzamanidou; M Migkou; M Gavriatopoulou; M Roussou; A Tasidou; M A Dimopoulos
Journal:  Leukemia       Date:  2012-11-06       Impact factor: 11.528

View more
  7 in total

Review 1.  What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.

Authors:  Bruno Almeida Costa; Tarek H Mouhieddine; Joshua Richter
Journal:  Target Oncol       Date:  2022-06-30       Impact factor: 4.864

2.  A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.

Authors:  Christina Mark; Jay Warrick; Natalie S Callander; Peiman Hematti; Shigeki Miyamoto
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

3.  PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival.

Authors:  Tyler Moser-Katz; Catherine M Gavile; Benjamin G Barwick; Kelvin P Lee; Lawrence H Boise
Journal:  Mol Cancer Res       Date:  2022-07-06       Impact factor: 6.333

4.  Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling.

Authors:  Qiang-Sheng Wang; Qi-Qin Shi; Ye Meng; Meng-Ping Chen; Jian Hou
Journal:  Front Genet       Date:  2022-05-26       Impact factor: 4.772

Review 5.  CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.

Authors:  Jędrzej Borowczak; Krzysztof Szczerbowski; Navid Ahmadi; Łukasz Szylberg
Journal:  Med Oncol       Date:  2022-01-29       Impact factor: 3.064

Review 6.  Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.

Authors:  Michael D Diamantidis; Sofia Papadaki; Evdoxia Hatjiharissi
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

Review 7.  A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments.

Authors:  Rosario Hervás-Salcedo; Beatriz Martín-Antonio
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.